Key facts
- It has raised $100K; the latest was Seed Round ($100K) in Jan 2025.
- Notable investors include NLC Health Ventures, Utrechtinc.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Persuasive Dx
- ·The full record, as it builds
Funding rounds
No funding rounds for Persuasive Dx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Persuasive Dx
Developer of diagnostic blood testing technology designed for high-throughput analysis of extracellular vesicles. The company specializes in extracellular vesicle protein signatures that can identify stable angina patients in the general practitioner setting, providing the healthcare sector with patented biomarker signatures for the early detection of stable angina in chest pain patients.
- Sector
- Healthcare
- HQ
- Utrecht, Netherlands
- Founded
- 2019
- Website
- persuasivedx.com/
- Ownership
- Privately Held (backing)
Persuasive Dx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Persuasive Dx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Persuasive Dx in its N-PORT filings yet. We sweep new filings monthly.